Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 693-694

  Steensma, David P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM; CREATININE; DANAZOL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN;

ANEMIA; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEATH; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOFIBROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

ANEMIA; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GREECE; HEMATINICS; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; SELECTION BIAS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 51449099373     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21244     Document Type: Editorial

References (13)

1. Katodritou E, Verrou E, Gastari V, et al. Erythropoiesis stimulating agents (ESA) are associated with reduced survival in patients with multiple myeloma. Am J Hematol, in press.
2. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
3. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007;20:637-664.
4. Baz R, Walker E, Choueiri TK, et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007;117:162-167.
5. Prutchi-Sagiv S, Golishevsky N, Oster HS, et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: Could it be beneficial in early disease? Br J Haematol 2006;135:660-672.
6. Mittelman M, Zeidman A, Kanter P, et al. Erythropoietin has an anti-myeloma effect - A hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 2004;72:155-165.
7. Ludwig H, Pohl G, Osterborg A. Anemia in multiple myeloma. Clin Adv Hematol Oncol 2004;2:233-241.
8. Ludwig H, Fritz E, Kotzmann H, Gisslinger H. Erythropoietin treatment of tumor-associated anemia in patients with multiple myeloma. Onkologie 1990;13:46-49.
9. Oster W, Herrmann F, Gamm H, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990;8:956-962.
10. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
11. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
12. Grimes DA, Schulz KF. Cohort studies: Marching towards outcomes. Lancet 2002;359:341-345.
13. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.